Active, not recruitingPhase 1NCT05411497

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Studying Dendritic cell tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Leif Bergsagel, M.D.
Mayo Clinic Hospital in Arizona
Intervention
Autologous MUC1-activated T-cells(biological)
Enrollment
5 target
Eligibility
18 years · All sexes
Timeline
2022 – 2027

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05411497 on ClinicalTrials.gov

Other trials for Dendritic cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Dendritic cell tumor →

← Back to all trials